THE EFFICACY OF RECOMBINANT ACTIVATED FACTOR VII (COAGIL VII) FOR TREATMENT HAEMORRHAGE AND HAEMOSTASIS DISORDES DURING THORACIC AORTA OPERATIONS
https://doi.org/10.21292/2078-5658-2019-16-3-25-31
Abstract
Goal: to evaluate the efficacy and safety of domestic (home-produced) recombinant factor VIIa (Coagil VII) for massive bleeding and haemostasis disordes treatment in thoracic aorta surgery.
Methods. 82 patients undergoing surgery on thoracic aorta with cardiopulmonary bypass and circulatory arrest s were divided in 3 groups. The 1 group included 27 patients with uncomplicated operations, moderate hemorrhage and standart protocol hemostasis management after cardiopulmonary bypass. In 2 group of 26 patients with massive hemorrhage the thrombocytes were used for treatment. In 3 main group (29 patients) with continious bleeding Coagil VII was used additionally.
Results. Coagil-VII induction in dose 37–100 mcg/kg was accompanied by prominent decreasing of wound bleeding in 20–25 min, that it allowed to perform sternoraphia. The volume of transfused erythrocytes , fresh frozen plasma and postoperative blood loss were less in comparison with control group and patients where the platelets were used. There were no any complications after Coagil VII induction. Analysis of the hemostasis indices showed decrease of APTT by 13%, PTT by 17% and MNO by 36% after Coagil VII induction.
Conclusion. The domestic recombinant factor VIIa (Coagil VII) in dose 66 ± 19,5 mcg/kg is an effective and safe medicine for bleeding and hаemostasis desordes treatment in the patients undergoing aortic surgery
About the Authors
N. A. TREKOVA
B. V. Petrovsky Russian Research Surgery Center
Russian Federation
Russian Federation
Nina A. Trekova Chief Researcher of Anesthesiology and Intensive Care Department no. II.
Phone: +7 (499) 246‒97‒91
2, Abrikosovsky Lane, Moscow, 119991
D. A. GUSKOV
B. V. Petrovsky Russian Research Surgery Center
Russian Federation
Russian Federation
Denis A. Guskov Anesthesiologist and Emergency Physician of Anesthesiology and Intensive Care Department no. II
2, Abrikosovsky Lane, Moscow, 119991
A. V. GONCHAROVA
B. V. Petrovsky Russian Research Surgery Center
Russian Federation
Russian Federation
Alevtina V. Goncharova Doctor of Clinical Laboratory Diagnostics of Research Clinical Laboratory.
Phone: +7 (499) 248‒58‒66
2, Abrikosovsky Lane, Moscow, 119991
B. A. AKSELROD
B. V. Petrovsky Russian Research Surgery Center
Russian Federation
Russian Federation
Boris A. Akselrod Head of Anesthesiology and Intensive Care Department no II
2, Abrikosovsky Lane, Moscow, 119991
References
1. Аndreeva T.А., Zorenko V.Yu., Davydkin I.L.et al. Efficacy and safety of Oktofactor in the treatment of patients with severe and moderate haemophilia A (results of phase II and III clinical trial, part 2). Voprosy Gematologii/Onkologii i Immunopatologii v Pediatrii, 2013, vol. 12, no. 4, pp. 31–37. (In Russ.)
2. Galstyan G.M., Polevodova O.А., Terekhova I.V. et al. Use of thromboelastography, throbin generation test and clotting tests to assess efficacy of homeostatic therapy with recombinant activated factor VII in the patients with the inhibitory form of hemophilia, Ros. Journal Detskoy Gematologii i Onkologii, 2017, no. 4, pp. 33–38. (In Russ.)
3. Gladysheva V.G. Vliyanie aktivirovannogo faktora VII na gemostaticheskiy potentsial pri massivnykh refrakternykh krovotecheniyakh u kardiokhirurgicheskikh bolnykh. Avtoref. diss. kand. med. nauk. [Impact of recombinant activated factor VII on homeostatic potential in case of massive refractory bleeding in the patients undergoing cardiac surgery. Cand. Diss. Synopsis]. Moscow, 2006.
4. Davydkin I.L., Аndreeva T.А., Zorenko V.Yu. et al. Efficacy and safety of Oktofactor in the preventive treatment of patients with severe and moderate haemophilia A (results of phase II and III clinical trial, part 1). Voprosy Gematologii/Onkologii i Immunopatologii v Pediatrii, 2013, vol. 12, no. 3, pp. 29–37. (In Russ.)
5. Dementieva I.I., Gladysheva V.G., Morozov Yu.А. The impact of the drug of Novo Seven on the volume of hemotransfusions in the patients undergoing cardiac surgery and suffering from increased hemophilia of non-surgical genesis. Vestnik Intensivnoy Terapii, 2005, no. 3, pp. 59–61. (In Russ.)
6. Dementieva I.I., Charnaya M.А., Morozov Yu.А. et al. Ispolzovanie gemostatika Novo-Seven u bolnykh s massivnoy gemorragiey pri krupnykh khirurgicheskikh vmeshatelstvakh. Posobiye dlya vrachey. [The use of the homeostatic of Novo Seven in the patients with massive hemorrhage undergoing massive surgery. Doctors' Manual]. Moscow, MAKS Press Publ., 2004, 32 p.
7. Dementieva I.I., Charnaya M.А., Morozov Yu.А. The first experience of using recombinant activated factor VII (Сoagil-VII) manufactured in Russia in massive refractory hemorrhage in cardiac surgery. Kardiologiya i Serdechno-Sosudistaya Khirurgiya, 2014, no. 3, pp. 74–75. (In Russ.)
8. Zorenko V.Yu., Polyanskaya T.Yu., Galstyan G.M. et al. The experience of using Сoagil-VII in orthopedic surgery in the patients with inhibitory hemophilia A. Voprosy Gematologii i Immunopatologii v Pediatrii, 2011, no. 3, pp. 35–40. (In Russ.)
9. Ivanov R., Sekareva G., Kravtsova O.et al. Rules for running trails of biosimilar medicines (biosimilars). Farmakokinetika i Farmakodinamika, 2014, no. 1, pp. 21–36. (In Russ.)
10. Kuznik B.I., Sturov V.G., Levshin N.Yu. et al. Gemorragicheskie i tromboticheskie zabolevaniya i sindromy u detey i podrostkov: Patogenez, klinika, diagnostika, terapiya i profilaktika. [Haemorrhagic and trombotic disorders and syndromes in children and adolescents: Pathogenesis, symptoms, diagnostics, therapy, and prevention]. 2nd ed., suppl. and amend., Novosibirsk, Nauka Publ., 2018, 524 p.
11. Nekhaev I.V., Prikhodchenko А.O., Lomidze S.V. et al. Eptacog alfa. The experience of use. Tromboz, Gemostaz i Reologiya, 2017, no. 4, pp. 63-69. (In Russ.)
12. Rybka M.M., Samsonova N.N., Lobacheva G.V. et al. Efficacy and safety of Сoagil-VII-eptacog alfa (activated) in surgical management of congenital heart disorders in newborns and children of the tender age. Tromboz, Gemostaz i Reologiya, 2014, no. 1, pp. 9–14. (In Russ.)
13. Samsonova N.N., Klimovich L.G., Diasamidze K.E. et al. The use of recombinant activated factor in cardiac surgery. Tromboz, Gemostaz i Reologiya, 2011, no. 4, pp. 41–46. (In Russ.)
14. Samsonova N.N., Rybka M.M. Efficacy of the management of hemostasis disorders with the recombinant activated factor of Сoagil-VII, concentrated prothrombin complex in the peri-operative period in the patients undergoing cardiac surgery. Tromboz, Gemostaz i Reologiya, 2016, no. S3(67), pp. 369–370. (In Russ.)
15. Samsonova N.N., Rybka M.M., Lobacheva G.V. et al. The study of efficacy and safety of Сoagil-VII-eptacog alfa (activated) in the patients with hemophilia undergoing surgery with cardiac pulmonary bypass. Tromboz, Gemostaz i Reologiya, 2012, no. 3, pp. 51-53. (In Russ.)
16. Trekova N.А., Solovova L.E., Guskov D.А. ey al. Transfusion tactics during cardiac and aortic surgery. Anesteziologiya i Reanimatologiya, 2014, no. 3, pp. 4–10. (In Russ.)
17. Fedorova T.А., Strelnikova E.V. Recombinant activated coagulation factor VII in the management of massive obstetric hemorrhage (literature review). Meditsinsky Soviet, 2014, no. 9, pp. 68–75. (In Russ.)
18. Aledort L. Comparative trombotic incidence after infusion of recombinant factor VII a versus factor VII inhibitor bypass activity. J. Thromb. Haemost., 2004, no. 2, pp. 1700‒1708.
19. DiDomenico R., Massad M., Krodonu J. et al. Use of recombinant activated factor VII for bleeding following operations requiring cardiopulmonary bypass. Chest, 2005, vol. 127, no. 5, pp. 1828‒1835.
20. Francyni M. Tht use of recombinant activated factor VII in platelet disordes. Blood Transfus., 2009, vol. 7, pp. 24‒28.
21. Ganter M., Schmuck S., Hamiel C. еt al. Monitoring recоmbinant factor VIIa treatment: efficacy depends on high levels of fibrinogen in a model of severe dilutional coagulopathy. J. Cardiothorac. Vasc. Anesth., 2008, vol. 22, no. 5, pp. 675‒680.
22. Ng H.J. Two cases of trombosis associated with use of recоmbinant factor VIIa in Singapore. 7 Novo Nordisk symposium on haemostasis management. 2003, abstracts. pp. 26
23. Robinson K., Savoia H., Street A. Trombotic complications in two patients receiving Novoseven. Haemophilia, 2000, no. 6, pp. 343‒346.
Review
For citations:
TREKOVA N.A., GUSKOV D.A., GONCHAROVA A.V., AKSELROD B.A. THE EFFICACY OF RECOMBINANT ACTIVATED FACTOR VII (COAGIL VII) FOR TREATMENT HAEMORRHAGE AND HAEMOSTASIS DISORDES DURING THORACIC AORTA OPERATIONS. Messenger of ANESTHESIOLOGY AND RESUSCITATION. 2019;16(3):25-32. (In Russ.) https://doi.org/10.21292/2078-5658-2019-16-3-25-31
Email this article 